Fort Washington Investment Advisors Inc. OH Reduces Holdings in Bristol Myers Squibb Company $BMY

Fort Washington Investment Advisors Inc. OH decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,605,927 shares of the biopharmaceutical company’s stock after selling 120,333 shares during the period. Bristol Myers Squibb makes up about 0.9% of Fort Washington Investment Advisors Inc. OH’s investment portfolio, making the stock its 25th largest position. Fort Washington Investment Advisors Inc. OH’s holdings in Bristol Myers Squibb were worth $158,049,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Union Bancaire Privee UBP SA raised its position in Bristol Myers Squibb by 12.6% in the 1st quarter. Union Bancaire Privee UBP SA now owns 569,583 shares of the biopharmaceutical company’s stock worth $32,087,000 after purchasing an additional 63,563 shares during the period. Sterling Capital Management LLC boosted its position in shares of Bristol Myers Squibb by 442.1% during the first quarter. Sterling Capital Management LLC now owns 170,257 shares of the biopharmaceutical company’s stock valued at $10,326,000 after buying an additional 138,851 shares during the period. Cambient Family Office LLC grew its stake in shares of Bristol Myers Squibb by 4.0% during the first quarter. Cambient Family Office LLC now owns 6,726 shares of the biopharmaceutical company’s stock valued at $408,000 after buying an additional 260 shares during the last quarter. Lewis Asset Management LLC raised its holdings in shares of Bristol Myers Squibb by 2.2% in the first quarter. Lewis Asset Management LLC now owns 11,551 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 253 shares during the period. Finally, River Street Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the first quarter worth approximately $300,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $57.45 on Friday. The firm has a 50 day moving average of $57.06 and a 200 day moving average of $57.27. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The company has a market capitalization of $117.31 billion, a price-to-earnings ratio of 16.14, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday. HSBC lifted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Guggenheim reaffirmed a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Bank of America lowered their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Finally, UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.